Revenue growth and raised guidance confirm strong commercial execution. The ITM merger and Pixclara approval are major catalysts. Monitor shareholder vote on December 1, 2026, and BLA resubmission for Zircaix. The stock may re-rate on the combination of commercial momentum and pipeline expansion.
Price Chart
Executive Summary
Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% YoY, driven by 30% growth in Precision Medicine revenue. The company reaffirmed FY 2026 revenue guidance at the upper end of US$950M-US$970M plus US$40M other income, and announced a transformative merger with ITM for US$1.65 billion upfront. FDA approval of Pixclara for glioma imaging and strong pipeline progress support the positive outlook.
Key Facts
- Q3 2026 group revenue US$245M, +19% YoY (Q3 2025: US$206M)
- Precision Medicine revenue US$201M, +30% YoY (Q3 2025: US$155M)
- FY 2026 revenue guidance reaffirmed at upper end: US$950M-US$970M, plus US$40M other income, total >US$1B
- FDA approved Pixclara (floretyrosine F 18) for glioma imaging, first approved imaging agent for this indication in the U.S.
- Announced merger with ITM for US$1.65B upfront consideration (US$1.25B in Telix shares + up to US$700M contingent)
- BiPASS Phase 3 study completed enrollment (350 patients); FDA granted Fast Track Designation
- FY 2026 R&D guidance revised to US$240M-US$260M (from US$230M-US$270M)
- Q3 2026 revenue sequentially flat vs Q2 2026 (US$247M), down 1%
- TMS (third-party) revenue US$44M, -6% YoY (Q3 2025: US$47M)
Financial Impact
Q3 revenue beat consensus expectations with 19% YoY growth; FY guidance implies ~$1B total revenue, a significant milestone. The ITM merger at $1.65B upfront is transformative, adding a late-stage therapeutic pipeline and isotope production capabilities.
Risk Factors
- ITM merger requires shareholder approval and customary closing conditions; deal risk exists
- BLA resubmission for Zircaix (TLX250-Px) pending; CRL addressed but FDA outcome uncertain
- R&D spending increasing (revised guidance US$240M-US$260M) may pressure near-term margins
- TMS third-party revenue declined 6% YoY, indicating potential headwinds in that segment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-066581 |
| Document: q32026resultsannouncement.htm | 0001628280-26-066581 |
| Document: 0001628280-26-066581-index-headers.html | 0001628280-26-066581 |
| Document: 0001628280-26-066581-index.html | 0001628280-26-066581 |
| Document: 0001628280-26-066581.txt | 0001628280-26-066581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.03 (−9.97%) |
Oct 20, 2026 7d ago | Press Release | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $9.03 (−9.97%) |
Sep 29, 2026 28d ago | 6-K | $10.97 $10.72 | ▼ −2.28% | ▼ −2.46% | $9.03 (−17.68%) |
Sep 21, 2026 5w ago | 6-K | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.03 (−20.16%) |
Sep 20, 2026 5w ago | Press Release | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $9.03 (−20.16%) |
Sep 14, 2026 6w ago | 6-K | $12.83 $11.83 | ▼ −7.79% | ▼ −7.35% | $9.03 (−29.62%) |
Sep 14, 2026 6w ago | Press Release | $11.78 $12.83 | ▲ +8.91% | ▲ +9.37% | $9.03 (−23.34%) |
Sep 1, 2026 8w ago | 6-K | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.03 (−21.14%) |
Sep 1, 2026 8w ago | Press Release | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $9.03 (−21.14%) |
Aug 19, 2026 9w ago | 6-K | $12.42 $11.33 | ▼ −8.78% | ▼ −9.19% | $9.03 (−27.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers